News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News ACC 2022 Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70 Michael O'Riordan April 07, 2022
News Daily News Homozygous FH Diagnosis Often Comes Late, With Lackluster Care Michael O'Riordan February 10, 2022
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Daily News FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels Michael O'Riordan December 22, 2021
News Daily News British Medical Groups Express Concern About Inclisiran Rollout Michael O'Riordan December 14, 2021
News Conference News AHA 2021 An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops Shelley Wood November 15, 2021
News Daily News Polygenic Risk Score IDs People at Risk for Early MI, Death Todd Neale October 26, 2021
News Daily News Cumulative Burden of LDL Cholesterol Increases CHD Risk Michael O'Riordan September 23, 2021
News Daily News Heterozygous FH Diagnosed Late, Remains Undertreated Michael O'Riordan September 13, 2021
News Conference News EAS 2021 For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short Michael O'Riordan June 03, 2021
News Daily News Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval Michael O'Riordan March 03, 2021
News Daily News FDA Passes on Inclisiran, Citing Manufacturing Site Problems Shelley Wood December 23, 2020
News Conference News ACC 2020 Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events Michael O'Riordan April 02, 2020
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for February 2020 Shelley Wood March 02, 2020
News Daily News CV Risk Factors in Youth May Prove Indelible for Later CAD Marcus A. Banks July 17, 2019
News Conference News EAS 2019 Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality Michael O'Riordan June 05, 2019
News Conference News EAS 2019 Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION Michael O'Riordan June 04, 2019
News Conference News SCAI 2019 LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER Yael L. Maxwell June 03, 2019
News Conference News EAS 2019 FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis Michael O'Riordan June 03, 2019